Impact of cholangiocarcinoma (CC) molecular heterogeneity on outcome during first-line chemotherapy and access to targeted therapies in early clinical trials (CT).

Abstract

4091Background: CC has poor prognosis and limited therapeutic options beyond first-line therapy. It is molecularly heterogeneous with several gene alterations (alt) that can be matched to targeted ...